Discloses is a pharmaceutical composition formulated for sublingual or buccal administration, which comprises: (a) a lysate or cell wall extract from a Gram-positive bacteria, or a pharmaceutically acceptable salt thereof, in an amount ranging from 1 mg/kg to 100 mg/kg (b) an oral-mucosa-transit promoter to assist in the therapeutic delivery of the said lysate or cell wall extract from a Gram-positive bacteria, or a pharmaceutically acceptable salt thereof, across a subject&rsquos oral mucosa and (c) an optional carrier, wherein the composition is formulated to completely dissolve in not less than 1 minute after administration. The composition is suitable for the treatment of a hepatic disease or disorder selected from hepatitis A infection, hepatitis B infection, hepatitis C infection, acute hepatitis, chronic hepatitis, or fulminant liver failure.
